Staphylococcus (e.g., Staphylococcus Aureus, Etc.) Patents (Class 514/2.7)
  • Publication number: 20120309676
    Abstract: Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant Staphylococcus aureus (MRSA) infection. The salts have an aqueous solubility of 2.5 mg/mL or more.
    Type: Application
    Filed: February 1, 2011
    Publication date: December 6, 2012
    Inventors: Sjoerd Nicolaas Wadman, Antony Nicholas Appleyard
  • Publication number: 20120308638
    Abstract: The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
    Type: Application
    Filed: December 16, 2010
    Publication date: December 6, 2012
    Inventors: Mathew Upton, Stephanie Sandiford
  • Patent number: 8318661
    Abstract: The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: November 27, 2012
    Assignee: Omnio Healer AB
    Inventors: Tor Ny, Jinan Li, Yongzhi Guo
  • Publication number: 20120295839
    Abstract: Methods of treatment or prophylaxis of bacterial vaginosis, prevention of recurrence of bacterial vaginosis and alleviation or prevention of symptoms or diagnostic criteria of bacterial vaginosis are provided. The methods include administration of an effective amount of a macromolecule comprising a polylysine, polyamidoamine, poly(etherhydroxyamine) or poly(propyleneimine) dendrimer and one or more sulfonic acid containing moieties attached thereto.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 22, 2012
    Applicant: STARPHARMA PTY LIMITED
    Inventors: Jeremy Robert Arthur Paull, Jacinth Kincaid Fairley, Clare Frances Price, Gareth Rhys Lewis
  • Publication number: 20120289456
    Abstract: Several bacterial species were isolated from marine segment obtained from seabed sediment at depths exceeding 1700 feet. At least four of the bacteria produced a compound that showed antibacterial activity against one or more multiple-drug-resistant (MDR) bacteria isolated from hospitals and clinics. One isolate, SJCH-12, exhibited a broad range of activity against MDR strains tested, including methicillin resistant Staphylococcus aureus (MRSA).
    Type: Application
    Filed: February 10, 2012
    Publication date: November 15, 2012
    Applicant: ST. JOSEPH'S CHILDREN'S HOSPITAL
    Inventors: MICHAEL J. P. LAWMAN, Selena Savell, Shabnam Eidizadeh
  • Patent number: 8299020
    Abstract: The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: October 30, 2012
    Assignee: The Ohio State University Research Foundation
    Inventors: Ahmed El-Meleigy Yousef, Zengguo He, Chunhua Yuan, Liwen Zhang, Duygu Kisla
  • Publication number: 20120245079
    Abstract: Provided are high affinity T cell receptor variable regions that are useful for treating diseases caused by superantigens including atopic dermatitis, pneumonia and delayed wound healing. The variable regions contain mutants that result in high affinity binding to the superantigen.
    Type: Application
    Filed: September 3, 2010
    Publication date: September 27, 2012
    Inventors: David M. Kranz, Patrick Schlievert
  • Publication number: 20120202736
    Abstract: The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria, fungi, and parasites. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: DOBEEL CORPORATION
    Inventors: Hong Mo MOON, Jung Sun YUM, Byung Cheol AHN, Joo Youn LEE
  • Publication number: 20120196791
    Abstract: Methods for treating a bacterial infection in a mammal in need thereof, and compositions related thereto, are disclosed, the methods comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound and a second antibacterial agent.
    Type: Application
    Filed: December 15, 2011
    Publication date: August 2, 2012
    Applicant: Achaogen, Inc.
    Inventors: Eliana Saxon Armstrong, Jon B. Bruss
  • Publication number: 20120189682
    Abstract: The present invention relates to a product comprising at least two antibiofilm agents wherein at least one of the antibiofilm agents is an antimicrobial peptide. The second antibiofilm agent is generally a dispersant or an anti-adhesive agent. There is also provided the use of the product in the treatment of a microbial infection.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 26, 2012
    Applicant: Novabiotics Limited
    Inventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
  • Publication number: 20120172289
    Abstract: The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection.
    Type: Application
    Filed: December 28, 2011
    Publication date: July 5, 2012
    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Bengang Xing, Tingting Jiang, Roushen Liew
  • Publication number: 20120165276
    Abstract: Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.
    Type: Application
    Filed: May 6, 2008
    Publication date: June 28, 2012
    Applicant: Mpex Pharmaceuticals, Inc.
    Inventors: TOMASZ GLINKA, Olga Lomovskaya, Keith Bostian, David M. Wallace
  • Publication number: 20120156295
    Abstract: Purified compounds of formula I are described. Compounds include all stereoisomeric forms and all tautomeric forms of the compounds of formula I and pharmaceutically acceptable salts and derivatives. Processes for the production of the antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections are described.
    Type: Application
    Filed: August 31, 2010
    Publication date: June 21, 2012
    Inventors: Prabhu Dutt Mishra, Girish Badrinath Mahajan
  • Publication number: 20120157371
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: December 12, 2011
    Publication date: June 21, 2012
    Inventors: Chongxi YU, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
  • Publication number: 20120128701
    Abstract: Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system.
    Type: Application
    Filed: September 9, 2011
    Publication date: May 24, 2012
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Publication number: 20120128673
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat S. aureus infection, in particular, S. aureus infections of the lungs. Also provided are use agonists and antagonists of PILR? and PILR?, respectively, to prevent such infections.
    Type: Application
    Filed: May 14, 2010
    Publication date: May 24, 2012
    Applicant: Schering Corporation
    Inventors: Antara Banerjee, Paul G. Heyworth
  • Publication number: 20120128622
    Abstract: The present invention is directed to an enhanced wound healing composition, including a gel containing vancomycin, useful for the prevention of the spread of resistant-type bacteria. Preferably, the drug is one or more antibiotic agents in therapeutically effective concentrations to reduce or eliminate MRSA. The composition is based on a gel composition containing one or more gel forming compounds, such as one or more polymers, preservatives, and/or pH stabilizers and buffers, which not only maintains a moist wound environment to enhance wound healing, but also provides an antibiotic agent which has sustained potency and stability. The composition, when placed in contact with a treatment site, delivers the drug to the site. By incorporating the drug into the gel composition that is formulated to enhance wound healing, the treatment of such disease is possible in a manner which promotes wound healing while reducing or eliminating the MRSA microbe.
    Type: Application
    Filed: November 17, 2011
    Publication date: May 24, 2012
    Inventor: Robert Stanley Berman
  • Publication number: 20120115774
    Abstract: In some aspects, the present invention provides ultrashort lipopeptides which feature ?-amino acids or ?-peptides and demonstrate antimicrobial activity. Accordingly, some aspects of the present invention provide lipopeptide compositions and methods of making and using the compositions as antimicrobial agents.
    Type: Application
    Filed: February 23, 2010
    Publication date: May 10, 2012
    Applicant: UNIVERSITY OF MANITOBA
    Inventors: George Zhanel, Frank Schweizer
  • Publication number: 20120108498
    Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.
    Type: Application
    Filed: October 1, 2010
    Publication date: May 3, 2012
    Applicant: Academia Sinica
    Inventors: Tsung-Lin Li, Yu-Chen Liu, Yi-Shan Li, Syue-Yi Lyu
  • Publication number: 20120108499
    Abstract: The invention relates to new peptoid compounds of formula (I), as well as their use in the treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms, and to compositions thereof.
    Type: Application
    Filed: September 6, 2011
    Publication date: May 3, 2012
    Applicant: University of Wollongong
    Inventors: John BREMNER, Stephen PYNE, Paul KELLER, Dan COGHLAN, Adel GARAS, Helen WITCHARD, Tim BOYLE, Jonathan COATES
  • Publication number: 20120088671
    Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
    Type: Application
    Filed: October 6, 2011
    Publication date: April 12, 2012
    Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
    Inventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
  • Publication number: 20120071398
    Abstract: The present invention relates to peptides comprising amino acids according to Formula I ((X)l(Y)m)n??(I) wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment of microbial infections.
    Type: Application
    Filed: November 30, 2011
    Publication date: March 22, 2012
    Applicant: NOVABIOTICS LIMITED
    Inventor: Deborah O'Neil
  • Publication number: 20120064125
    Abstract: The present invention involves the use of activators of bacterial Agrquoroum-sensing systems to prevent or reverse biofilm formation in methicillin resistant Staphylococcus aureus (MRSA), or to restore sensitivity of MRSA bio films to antibiotics.
    Type: Application
    Filed: April 19, 2010
    Publication date: March 15, 2012
    Inventor: Alexander R. Horswill
  • Publication number: 20120058935
    Abstract: The invention features antimicrobial compositions comprising ?-amyloid peptides, oligomers, and analogs thereof, and methods of using them for the prevention or treatment of an infection.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 8, 2012
    Applicant: The General Hospital Corporation
    Inventors: Robert Moir, Rudolph E. Tanzi
  • Publication number: 20120052048
    Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
    Type: Application
    Filed: February 5, 2010
    Publication date: March 1, 2012
    Applicants: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A., TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA
    Inventors: Miguel Ängelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Sara Ferreira Llorente Grancho Lourenço
  • Publication number: 20120053115
    Abstract: The present invention relates to novel amide derivatives of the lantibiotic 97518 and their uses. In particular, the present invention describes novel compounds having general formula (II) and their use as antibiotic.
    Type: Application
    Filed: November 24, 2008
    Publication date: March 1, 2012
    Applicant: Sentinella Pharmaceuticals, Inc.
    Inventors: Sonia Ilaria Maffioli, Cristina Brunati, Donatella Potenza, Francesca Vasile, Stefano Donadio
  • Publication number: 20120040888
    Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
    Type: Application
    Filed: October 26, 2009
    Publication date: February 16, 2012
    Applicant: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Michael R. Yeaman, Arnold Bayer
  • Patent number: 8114657
    Abstract: Several bacterial species were isolated from marine segment obtained from seabed sediment at depths exceeding 1700 feet. At least four of the bacteria produced a compound that showed antibacterial activity against one or more multiple-drug-resistant (MDR) bacteria isolated from hospitals and clinics. One isolate, SJCH-12, exhibited a broad range of activity against MDR strains tested, including methicillin resistant Staphylococcus aureus (MRSA).
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: February 14, 2012
    Assignee: St. Joseph' Children' Hospital
    Inventors: Michael Lawman, Selena Braccili, Shabnam Eidizadeh
  • Publication number: 20120020940
    Abstract: The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity.
    Type: Application
    Filed: September 24, 2009
    Publication date: January 26, 2012
    Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)
    Inventors: Jörg Durner, Christian Lindermayr, Ruth Brack-Werner
  • Patent number: 8101575
    Abstract: Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: January 24, 2012
    Assignee: Theravance, Inc.
    Inventor: Michael R. Leadbetter
  • Publication number: 20120015873
    Abstract: The present invention finds application in the therapeutic fields. In particular, it concerns new synthetic melanocortin peptides having improved antimicrobial activity.
    Type: Application
    Filed: January 19, 2009
    Publication date: January 19, 2012
    Inventors: Anna Catania, Ferruccio Bonino, Paolo Grieco, Ettore Novellino
  • Publication number: 20110312876
    Abstract: Disclosed are diagnostic methods for determining a subtype of methicillin-resistant Staphylococcus aureus (MRSA) in a biological sample of a mammal. Methods include providing a biological sample of the mammal, performing a PCR analysis of the biological sample, and analyzing the PCR amplicons with respect to their sizes so as to determine for type I, type II, type III, type IV or type V MRSA that may be present in the biological sample. Further example embodiments include using at least one mecA primer pair and/or using at least one Staphylococcus aureus nuc primer pair in the PCR analysis. Further disclosed are methods for screening populations for MRSA, and methods of treating a mammal testing positive for Type IV MRSA. Also disclosed are kits for determining a MRSA subtype in a mammal and isolated primers that may be used in the present methods and kits.
    Type: Application
    Filed: January 13, 2011
    Publication date: December 22, 2011
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Scott Elliot Gygax, Christina Lim Overmyer, Lisa A. DeSalvia, Martin E. Adelson, Eli Mordechai
  • Publication number: 20110294723
    Abstract: The present disclosure relates to compounds of formula (II): pharmaceutical compositions comprising same and use of the compounds and compositions for the treatment of microbial infection, particularly Methicillin-resistant Staphylococcus aureus (MRSA) infection.
    Type: Application
    Filed: February 2, 2010
    Publication date: December 1, 2011
    Applicant: Novacta Biosystems Limited
    Inventor: Sjoerd Nicolaas Wadman
  • Publication number: 20110294721
    Abstract: The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid residues; or a p
    Type: Application
    Filed: September 24, 2009
    Publication date: December 1, 2011
    Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)
    Inventors: Jörg Durner, Christian Lindermayr, Ruth Brack-Werner
  • Publication number: 20110294722
    Abstract: The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity.
    Type: Application
    Filed: September 24, 2009
    Publication date: December 1, 2011
    Applicant: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWLET (GmbH)
    Inventors: Jörg Durner, Christian Lindermayr
  • Publication number: 20110268703
    Abstract: A strain of Enterococcus mundtii has probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. An isolated nucleotide sequence codes for the antimicrobial peptide (peptide ST4SA). A process is also provided for the production of a peptide which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 10° C. and 45° C., until a recoverable quantity of the peptide is produced, and recovering the peptide. The isolated peptide may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.
    Type: Application
    Filed: April 26, 2011
    Publication date: November 3, 2011
    Inventors: Leon Milner Theodore Dicks, Svetoslav Dimitrov Todorov, Hendriette Knoetze, Marelize Brink
  • Patent number: 8044022
    Abstract: Several species of bacteria capable of invasive infections, such as S. pyogenes, S. equi and P. multocida, contain hyaluronic acid (HA) in their capsules. Bacterial species such as Staphylococcus aureus and related Staphylococci have capsules that contain acidic polysaccharides. Bacterial capsule or bacterial surface binding peptides were synthesized and tested in a culture model of invasive bacterial infections, specifically translocation through polarized keratinocyte cultures. The peptides reduced the translocation of a variety of bacterial species, with a concomitant increase in bacterial internalization by the keratinocytes. In vivo, subcutaneous inoculation of encapsulated GAS treated with peptides delayed bacterial dissemination. In a mouse surgical wound model infected with S. aureus, treatment with peptides reduced the numbers of bacteria and inflammation at the wound site.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: October 25, 2011
    Inventors: Tadeusz Kolodka, Bernard T. Charlton, Wendy Johnson
  • Publication number: 20110257078
    Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.
    Type: Application
    Filed: July 17, 2009
    Publication date: October 20, 2011
    Applicant: E-THERAPEUTICS PLC
    Inventors: Malcolm Philip Young, Catherine Mary Thomas
  • Publication number: 20110245153
    Abstract: Stabilized variable regions of the T cell receptor and methods of making the same using directed evolution through yeast display are provided. In one embodiment, the variable region is variable beta. In one embodiment, the stabilized T cell receptor variable regions have high affinity for a superantigen, such as TSST-1 or SEB. These T cell receptor variable regions are useful as therapeutics.
    Type: Application
    Filed: March 15, 2007
    Publication date: October 6, 2011
    Applicant: National Institutes of Health (NIH), U. S. Dept. of Health and Human Resources (DHHS) U. S. Govt.
    Inventors: David M. Kranz, Rebecca A. Buonpane, Hywyn R.O. Churchill, Eric J. Sundberg, Beenu Moza, Patrick Schlievert
  • Publication number: 20110245152
    Abstract: The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
    Type: Application
    Filed: September 28, 2007
    Publication date: October 6, 2011
    Inventors: Ahmed El-Meleigy Yousef, Zengguo He, Chunhua Yuan, Liwen Zhang, Duygu Kisla
  • Publication number: 20110236359
    Abstract: The present invention relates to novel bacteriocin-producing lactic acid bacteria strains Lactococcus lactis subsp. lactis MM19 accession number NML-080508-01 and Pediococcus acidilactici MM33 accession number NML-080508-02 isolated from the human gut. The strains L. lactis subsp. lactis MM19 and P. acidilactici MM33 and the bacteriocins produced by these strains are useful for inhibiting microbial growth in food products, and for inhibiting microbial infection or colonization of a mammal.
    Type: Application
    Filed: September 4, 2008
    Publication date: September 29, 2011
    Applicant: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Monique Lacroix, Mathieu Millette
  • Patent number: 8003602
    Abstract: This invention relates to a novel purified compound PM181104, of formula: of molecular weight 1514 and molecular formula C69H66N18O13S5; which is obtained by fermentation of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269). The invention includes all stereoisomeric forms and all tautomeric forms of the compound PM181104 and pharmaceutically acceptable salts and derivatives such as esters and ethers. The present invention further relates to processes for the production of the novel antibacterial compound(s), to the production of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269), and to pharmaceutical compositions containing the novel compound(s) as an active ingredient and its/their use in medicines for treatment and prevention of diseases caused by bacterial infections.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: August 23, 2011
    Assignees: Piramal Life Sciences Limited, Council of Scientific and Industrial Research
    Inventors: Girish Badrinath Mahajan, Saji David George, Prafull Vasant Ranadive, Prabhu Dutt Satyanarayan Mishra, Sreekumar Sankaranarayanan Eyyammadichiyil, Rajan Mukund Panshikar, Satish Namdeo Sawant, Sridevi Krishna, Meenakshi Sivakumar, Koteppa Pari, Becky Mary Thomas, Zarine Eruch Patel, Ram Vishwakarma, Chandrakant Govind Naik, Lisette D'Souza, Prabha Devi
  • Publication number: 20110201546
    Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
    Type: Application
    Filed: August 29, 2009
    Publication date: August 18, 2011
    Applicant: TARGANTA THERAPEUTICS CORP.
    Inventors: Dario Lehoux, Thomas R Parr, Gregory Moeck, Pierre Etienne
  • Patent number: 7989416
    Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: August 2, 2011
    Assignee: Novacta Biosystems Limited
    Inventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
  • Publication number: 20110171304
    Abstract: A peptide comprising the sequence VKVKVRVKVDPPTKVKVRVKV-NH2 forms a hydrogel which has the ability to shear-thin and recover. The hydrogel, both before and after shear-thinning, is capable of killing bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
    Type: Application
    Filed: March 24, 2010
    Publication date: July 14, 2011
    Applicant: University of Delaware
    Inventors: Daphne A. Salick, Darrin J. Pochan, Joel P. Schneider
  • Publication number: 20110160124
    Abstract: Several bacterial species were isolated from marine segment obtained from seabed sediment at depths exceeding 1700 feet. At least four of the bacteria produced a compound that showed antibacterial activity against one or more multiple-drug-resistant (MDR) bacteria isolated from hospitals and clinics. One isolate, SJCH-12, exhibited a broad range of activity against MDR strains tested, including methicillin resistant Staphylococcus aureus (MRSA).
    Type: Application
    Filed: August 24, 2009
    Publication date: June 30, 2011
    Applicant: St. Joseph's Children's Hospital
    Inventors: Michael Lawman, Selena Braccili, Shabnam Eidizadeh
  • Publication number: 20110152176
    Abstract: The present invention involves the use of activators of bacterial agr quoroum-sensing systems to block, inhibit or reverse biofilm formation. The biofilm may be located on an industrial or medical surface, or may be located in a subject, such as in a wound or infected organ, or on an in-dwelling medical device.
    Type: Application
    Filed: May 27, 2009
    Publication date: June 23, 2011
    Inventor: Alexander R. Horswill
  • Publication number: 20110150780
    Abstract: Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containing photo-oxidized solubilizer.
    Type: Application
    Filed: November 15, 2007
    Publication date: June 23, 2011
    Applicant: Migenix Inc.
    Inventors: Timothy J. Krieger, Robert Taylor, Douglas Erfle, Janet R. Fraser, Michael H.P. West, Patricia J. McNichol
  • Publication number: 20110143992
    Abstract: Disclosed herein are methods and compositions related to GHS-R antagonists.
    Type: Application
    Filed: February 13, 2007
    Publication date: June 16, 2011
    Inventors: Dennis Taub, Vishwa Deep Dixit
  • Publication number: 20110130326
    Abstract: The present invention relates to methods for treating infective endocarditis, such as bacterial endocarditis, with defensin polypeptides.
    Type: Application
    Filed: November 30, 2010
    Publication date: June 2, 2011
    Applicant: Novozymes A/S
    Inventor: Hans-Henrik Kristensen Hoeghenhaug